belimumab: clinical use

Prescribing considerations

• Initiate and supervise treatment through clinicians experienced in managing systemic lupus erythematosus.
• Assess active or recurrent infection, vaccination status, psychiatric history and suicide risk before treatment.
• Review immunoglobulin deficiency, hepatitis, HIV, transplant and malignancy history; several of these populations were not studied and treatment is not recommended.
• Consider pneumococcal vaccination before initiation and avoid live vaccines around treatment.
• Record the product name and batch number for biologic traceability.

Contraindications and cautions

• Hypersensitivity to belimumab or any formulation excipient.

Monitoring

• Monitor disease control and ongoing need for therapy.
• Monitor for infection, hypersensitivity, severe skin reactions and new neurological or psychiatric symptoms.
• If serious infection develops, consider interrupting immunosuppressive treatment until it resolves.
• Suspend belimumab if progressive multifocal leukoencephalopathy is suspected; discontinue if confirmed.
• Continue monitoring required for concomitant immunosuppressive therapies.

Clinical pharmacology

Belimumab is a recombinant human IgG1λ monoclonal antibody targeting soluble BLyS/BAFF. It is expected to be degraded by proteolysis into peptides and amino acids rather than undergoing conventional hepatic metabolism.

Formulation and product differences

• The pre-filled pen contains a ready-to-use solution for subcutaneous administration after training.
• The intravenous formulation is a powder requiring aseptic reconstitution and dilution, and must be administered by infusion rather than intravenous bolus.
• Both routes can cause systemic hypersensitivity reactions; infusion treatment requires an appropriately equipped clinical setting.
• Injection-site reactions apply specifically to the subcutaneous formulation.

Solution for infusion

Route: Intravenous

Strengths: 120 mg, 400 mg

Injection

Route: Parenteral

Strengths: 200 mg